Cellectar BioSciences, Inc.
(NASDAQ : CLRB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-3.80%191.441.2%$534.16m
TSROTESARO, Inc.
0.23%73.9514.4%$516.06m
CELGCelgene Corporation
-3.74%70.081.2%$510.98m
GILDGilead Sciences, Inc.
-2.91%68.150.9%$491.90m
ILMNIllumina, Inc.
-3.86%321.413.5%$363.96m
BIIBBiogen Inc.
-3.05%316.731.3%$352.14m
REGNRegeneron Pharmaceuticals, Inc.
-2.32%372.832.6%$248.08m
VRTXVertex Pharmaceuticals Incorporated
-4.12%172.211.9%$245.33m
AAgilent Technologies, Inc.
-2.34%70.231.5%$233.08m
ALXNAlexion Pharmaceuticals, Inc.
-4.49%115.602.0%$139.06m
SRPTSarepta Therapeutics, Inc.
-3.35%121.3815.4%$129.29m
NKTRNektar Therapeutics
-2.76%36.995.5%$106.49m
EXASExact Sciences Corporation
-4.30%71.7025.3%$105.84m
INCYIncyte Corporation
-0.91%64.512.5%$103.69m
LGNDLigand Pharmaceuticals Incorporated
-5.19%145.6123.1%$85.50m

Company Profile

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micrometastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on April 11, 2011 and is headquartered in Madison, WI.